Jose Manuel Otero is COO at Lexeo Therapeutics, Inc. (LXEO). They have made 8 open-market trades across 1 company since 2025, most recently 2026-09-14.
CIK 0002024096
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| LXEO | 138,288 | $364K |
Shares reported on the most recent Form 4, priced at the 2026-09-28 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LXEO | SELL | 2026-08-18 | 2026-08-19 | $4.96 | $6K | -10.8% | -21.4% | — |
| LXEO | SELL | 2026-07-01 | 2026-07-01 | $4.48 | $21K | +0.7% | -10.1% | -25.3% |
| LXEO | SELL | 2026-05-18 | 2026-05-20 | $5.07 | $7K | -10.4% | +0.4% | -1.4% |
| LXEO | SELL | 2026-02-18 | 2026-02-20 | $6.40 | $19K | +16.4% | -10.9% | -16.2% |
| LXEO | SELL | 2025-11-18 | 2026-02-20 | $9.27 | $7K | +16.4% | -10.9% | -16.2% |
| LXEO | SELL | 2025-10-17 | 2025-10-17 | $8.95 | $19K | +2.4% | -2.1% | -22.5% |
| LXEO | SELL | 2025-08-18 | 2025-08-20 | $4.67 | $13K | +1.1% | +8.6% | +93.7% |
| LXEO | SELL | 2025-08-18 | 2025-11-20 | $9.27 | $7K | -2.1% | +20.1% | -28.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.